AIC316 GmbH
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Jul 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 1, 2027The maintenance fee for Crystalline N-[5-(AMINOSULFONYL)-4-Methyl-1,3-Thiazol-2-YL]-N-METHYL-2-[4-(2-Pyridinyl)PHENYL]ACETAMIDE Mono Mesylate Monohydrate Having a Specific Particle Size Distribution Range and a Specific Surface Area Range for Use in Pharmaceutical Formulations (US 9,119,786) comes due Mar 1, 2027. Unpaid by Sep 1, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 19, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,784,887 | Pharmaceutical preparation of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide In force · From the USPTO record | In force | From the USPTO record | |
| US 9,119,786 | Crystalline N-[5-(AMINOSULFONYL)-4-Methyl-1,3-Thiazol-2-YL]-N-METHYL-2-[4-(2-Pyridinyl)PHENYL]ACETAMIDE Mono Mesylate Monohydrate Having a Specific Particle Size Distribution Range and a Specific Surface Area Range for Use in Pharmaceutical Formulations In force · High confidence | In force | High confidence | |
| US 9,340,535 | N-[5-(Aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate In force · From the USPTO record | In force | From the USPTO record | |
| US 9,592,225 | Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations In force · From the USPTO record | In force | From the USPTO record | |
| US RE49,697 | Crystalline N-[5-(AMINOSULFONYL)-4-Methyl-1,3-Thiazol-2-YL]-N- METHYL-2-[4-(2-Pyridinyl)PHENYL]ACETAMIDE Mono Mesylate Monohydrate Having a Specific Particle Size Distribution Range and a Specific Surface Area Range for Use in Pharmaceutical Formulations In force · Low confidence | In force | Low confidence | |
| US 9,889,124 | Crystalline N-[5-(AMINOSULFONYL)-4-Methyl-1,3-Thiazol-2-YL]-N-METHYL-2-[4-(2-Pyridinyl)PHENYL]ACETAMIDE Mono Mesylate Monohydrate Having a Specific Particle Size Distribution Range and a Specific Surface Area Range for Use in Pharmaceutical Formulations In force · Medium confidence | In force | Medium confidence | |
| US 11,021,474 | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,266,636 | A Maleate Salt of the Free Base of N-[5-(AMINOSULFONYL)-4-Methyl-1.3-Thiazol-2-YL]-N-METHYL-2-[4-(2-Pyridinyl)-PHENYL]-ACETAMIDE, Pharmaceutical Formulations, Methods of Manufacture and Uses Thereof for the Treatment of Herpes Viruses In force · High confidence | In force | High confidence | |
| US 12,070,451 | Sulfate Salt of the Free Base of N-[5-(AMINOSULFONYL)-4-Methyl-1,3-Thiazol-2-YL]-N-METHYL-2-[4-(2-Pyridinyl)-PHENYL]-ACETAMIDE, Pharmaceutical Formulations, Methods of Manufacture and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,213,516 | Intravaginally applicable devices comprising antiviral compounds In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 12: 1 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.